Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study

In the phase 3 POLLUX study, daratumumab plus lenalidomide and dexamethasone (DRd) significantly reduced the risk of progression/death and induced deeper responses vs. lenalidomide and dexamethasone alone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM). We report a subgroup analysi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Suzuki, Kenshi, Dimopoulos, Meletios A., Takezako, Naoki, Okamoto, Shinichiro, Shinagawa, Atsushi, Matsumoto, Morio, Kosugi, Hiroshi, Yoon, Sung-Soo, Huang, Shang-Yi, Qin, Xiang, Qi, Ming, Iida, Shinsuke
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5928154/
https://ncbi.nlm.nih.gov/pubmed/29712896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0071-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados